Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.92 |
| ▸ | GLB1 | P16278 | 1/20 | 0.84 |
| ▸ | GBA1 | P04062 | 10/20 | 0.74 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | GBA2 | Q9HCG7 | 11/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | UGCG | Q16739 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378221 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL2430983 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL3382092 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL15599058 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL2435897 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL2430985 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL15599026 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL2430986 | 1.00 | GUSB (0.92) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL18191086 | 0.98 | GUSB (0.88) | GUSBGLB1GBA1EBPSIGMAR1 | |
| SCHEMBL15599061 | 0.98 | GUSB (0.88) | GUSBGLB1GBA1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| WO-2014032184-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | GUSB 50/4885GLB1 138/4885GBA1 25/4885 |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | GUSB 50/4885GLB1 138/4885GBA1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.